title: Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.
abstract: OBJECTIVE
  Stent thrombosis (ST) is a major complication of percutaneous coronary interventions (PCIs). An invasive management by re-PCI is the commonly adopted treatment for ST, but data on outcome are limited.
  
  
  RESULTS
  We performed a 2-year multicentre registry enrolling consecutive patients with angiographically confirmed ST undergoing PCI. The primary angiographic endpoint was optimal angiographic reperfusion (TIMI 3 + blush grade 2 or 3). The primary clinical endpoints were death and major adverse coronary and cerebrovascular events (MACCEs) at 6 months. A total of 110 patients underwent 117 urgent PCI during the study. Patients with drug-eluting stent (DES) thrombosis, compared with those with bare metal stent (BMS) thrombosis, exhibited a higher rate of late or very late presentation and of anti-platelet therapy withdrawal. Optimal angiographic reperfusion was obtained in 64% of the patients. Death and MACCE rates at 6 months were 17 and 30%, respectively. Clinical outcome was similar for BMS and DES thrombosis. Very late ST, implantation of stent during PCI for ST, and failure to achieve optimal angiographic reperfusion were the independent predictors of 6-month mortality.
  
  
  CONCLUSIONS
  DES and BMS thromboses have different clinical features, but a similar poor outcome. Indeed, PCI for ST is associated with a low rate of reperfusion and to a high rate of death and MACCE, calling for action in order to prevent its occurrence and to improve its management.
authors.affiliation: Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. f.burzotta@rm.unicatt.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Burzotta
authors.forename: Antonio
authors.initials: A
authors.lastname: Parma
authors.forename: Christian
authors.initials: C
authors.lastname: Pristipino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Manzoli
authors.forename: Flavia
authors.initials: F
authors.lastname: Belloni
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
authors.forename: Stefano
authors.initials: S
authors.lastname: Rigattieri
authors.forename: Alessandro
authors.initials: A
authors.lastname: Danesi
authors.forename: Pietro
authors.initials: P
authors.lastname: Mazzarotto
authors.forename: Francesco
authors.initials: F
authors.lastname: Summaria
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.forename: Francesco
authors.initials: F
authors.lastname: Prati
authors.forename: Carlo
authors.initials: C
authors.lastname: Trani
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000401:mortality; D017023:Coronary Angiography / Q000706:statistics & numerical data; D003328:Coronary Thrombosis / Q000517:prevention & control* / Q000628:therapy; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015425:Myocardial Reperfusion / Q000379:methods* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D012042:Registries; D015607:Stents / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors